Similar articles

• Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.

  Horiguchi Y, Kuroda K, Nakashima J, Murai M, Umezawa K. Horiguchi Y, et al. Expert Rev Anticancer Ther. 2003 Dec;3(6):793-8. doi: 10.1586/14737140.3.6.793. Expert Rev Anticancer Ther. 2003. PMID: 14686701 Review.
• Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.

  Umezawa K. Umezawa K. Biomed Pharmacother. 2011 Jul;65(4):252-9. doi: 10.1016/j.biopha.2011.02.003. Epub 2011 Apr 8. Biomed Pharmacother. 2011. PMID: 21723080 Review.
• Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.

  Cvek B. Cvek B. Hum Reprod. 2009 Nov;24(11):2967; author reply 2967-8. doi: 10.1093/humrep/dep294. Epub 2009 Aug 17. Hum Reprod. 2009. PMID: 19687055 No abstract available.
• Can NF-kappaB be a target for novel and efficient anti-cancer agents?

  Olivier S, Robe P, Bours V. Olivier S, et al. Biochem Pharmacol. 2006 Oct 30;72(9):1054-68. doi: 10.1016/j.bcp.2006.07.023. Epub 2006 Sep 14. Biochem Pharmacol. 2006. PMID: 16973133 Review.
• Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.

  Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K, Murai M. Kikuchi E, et al. Cancer Res. 2003 Jan 1;63(1):107-10. Cancer Res. 2003. PMID: 12517785